101 438

Cited 19 times in

Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.

DC Field Value Language
dc.contributor.authorJung, HJ-
dc.contributor.authorChen, Z-
dc.contributor.authorMcCarty, N-
dc.date.accessioned2012-04-30T05:09:49Z-
dc.date.available2012-04-30T05:09:49Z-
dc.date.issued2011-
dc.identifier.issn1042-8194-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/6651-
dc.description.abstractWe recently identified clonogenic malignant stem cell populations in human mantle cell lymphoma (MCL), a particularly deadly subtype of non-Hodgkin lymphoma (NHL). We discovered that CD45+CD19- MCL cells, which we termed MCL-initiating cells (MCL-ICs), are highly tumorigenic and display self-renewal capacity in vivo; in contrast, CD45+CD19+ MCL cells, which constitute the vast majority of cells within the tumors, show no self-renewal capacity and greatly reduced tumorigenicity. Given the newly appreciated role of cancer-initiating cells in the drug resistance of cancers, it is critical to investigate whether CD45+CD19- MCL-ICs play a role in the drug resistance of human MCL. We discovered that MCL-ICs were more resistant to clinically relevant chemotherapeutic agents, in combination or in a single regimen, compared to CD45+CD19+ cells, and that this drug resistance was largely due to quiescent properties with enriched ABC transporters. In conclusion, designing novel therapies to kill CD45+CD19- MCL-ICs may prevent relapse and increase patient survival.-
dc.language.isoen-
dc.subject.MESHAntigens, CD19/metabolism-
dc.subject.MESHAntigens, CD45/metabolism-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/pharmacology-
dc.subject.MESHCell Survival/drug effects-
dc.subject.MESHCells, Cultured-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESH*Drug Resistance, Neoplasm-
dc.subject.MESHFlow Cytometry-
dc.subject.MESH*Gene Expression Regulation, Neoplastic-
dc.subject.MESHHumans-
dc.subject.MESHInhibitory Concentration 50-
dc.subject.MESHLymphoma, Mantle-Cell/genetics/metabolism/pathology-
dc.subject.MESHNeoplastic Stem Cells/drug effects/*metabolism/pathology-
dc.subject.MESHP-Glycoprotein/*genetics-
dc.subject.MESHReverse Transcriptase Polymerase Chain Reaction-
dc.titleStem-like tumor cells confer drug resistant properties to mantle cell lymphoma.-
dc.typeArticle-
dc.identifier.pmid21599592-
dc.identifier.urlhttp://informahealthcare.com/doi/abs/10.3109/10428194.2011.562570-
dc.contributor.affiliatedAuthor정, 현주-
dc.type.localJournal Papers-
dc.identifier.doi10.3109/10428194.2011.562570-
dc.citation.titleLeukemia & lymphoma-
dc.citation.volume52-
dc.citation.number6-
dc.citation.date2011-
dc.citation.startPage1066-
dc.citation.endPage1079-
dc.identifier.bibliographicCitationLeukemia & lymphoma, 52(6):1066-1079, 2011-
dc.identifier.eissn1029-2403-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
Files in This Item:
21599592.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse